CTOs on the Move


 
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.viz.ai

  • San Francisco, CA USA
  • Phone: 866.849.4980

Executives

Name Title Contact Details
Gad Sakin
CTO Profile

Funding

Viz raised $21M on 07/18/2018
Viz raised $50M on 10/23/2019
Viz raised $71M on 03/17/2021

Similar Companies

Medical Concepts Development

MCD is a quality, solution oriented manufacturer of adhesive coated films, pouches, tapes, and special purpose products. MCD is ISO 13485:1996 Certified. Operating from it's GMP compliant Woodbury, Minnesota facility, MCD develops, markets, and

AMT Electrosurgey

AMT Electrosurgey is a Kitchener, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Leimkuehler Inc

Leimkuehler Inc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dthera

Dthera™ Sciences (OTCQB:DTHR) is the leading digital therapeutic company focusing on the elderly. The San Diego-based, publicly traded company is working to improve the lives of seniors and individuals suffering from neurodegenerative diseases, as well as those who care for them. It has two core products: ReminX™, a commercially available consumer health product for individuals suffering from social isolation and dementia; and DTHR-ALZ, and a development-stage product that has been granted Breakthrough Device designation by the FDA for the mitigation of the symptoms of agitation and depression associated with Alzheimer`s disease.

Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,400 people across 40 countries.